

200.1079

IN THE UNITED STATES PATENT AND TRADEMARK OFFIC

Re:

Application of:

Ronald M. BURCH, et al.

Serial No.

10/033,055

Filed:

December 27, 2001

For:

SYNERGISTIC ANALGESIC COMBINATION

OF OXYCODONE AND CELECOXIB

PRELIMINARY AMENDMENT

Box Non-Fee Amendment Assistant Commissioner for Patents Washington, D.C. 20231

November 22, 2002

Sir:

Applicants respectfully request that the following amendments be made to the abovementioned application:

IN THE SPECIFICATION

Please amend the specification as follows:

At page 13, please amend the paragraph beginning at line 25 as follows:

- Certain preferred COX-2 inhibitors include celecoxib (SC-58635), 5-bromo-s-(4-fluorophenyl)-3-[4-(methylsufonyl)phenyl] thiophene (DUP-697), flosulide (CGP-28238), meloxicam, 6-methoxy-2 naphthylacetic acid (6-MNA), Vioxx (MK-966), nabumetone (prodrug for 6-MNA), nimesulide, N-[2-(cyclohexyloxy)-4-nitrophenyl] methanesulfonamide (NS-398), 1-fluoro-4-[2-[4-methylsufonyl)phenyl]-1-cyclopenten-1-yl] benzene (SC-5766), 5-(4-fluorophenyl)-1[4-(methylsufonyl)phenyl]-3-trifluoromethyl 1H-pyrazole (SC-58215), N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide (T-614); or

B